#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	4826	16S	1529	1529	99.87	16S.l15.c30.ctg.1	2471	573.8	0	.	n	.	0	A69G	SNP	69	69	A	444	444	G	691	G	640	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	4826	16S	1529	1529	99.87	16S.l15.c30.ctg.1	2471	573.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	1825	1825	T	747	T,C	706,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	4826	16S	1529	1529	99.87	16S.l15.c30.ctg.1	2471	573.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1559	1559	C	692	C,T	633,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	4826	16S	1529	1529	99.87	16S.l15.c30.ctg.1	2471	573.8	0	HET	.	.	.	C1358T,G	.	1358	1358	C	1733	1733	C	749	C,T,G	531,162,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7318	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4128	530.5	0	.	n	.	0	T695C	SNP	695	695	T	1368	1368	C	582	C,T,A,G	524,1,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7318	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4128	530.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2644	2644	C	577	C	524	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7318	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4128	530.5	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3270	3270	T	622	T,A	551,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7318	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4128	530.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2718	2718	A	635	A	571	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	766	folP	855	855	100.0	folP.l15.c4.ctg.1	2084	109.8	1	SNP	p	R229S	1	.	.	685	687	AGC	1358	1360	AGC	148;148;149	A,G;G;C	138,1;139;137	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1324	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3963	99.9	1	SNP	p	S91F	1	.	.	271	273	TTC	909	911	TTC	103;103;103	T,G;T,C;C	96,2;99,1;100	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1324	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3963	99.9	1	SNP	p	G95N	0	.	.	283	285	GGC	921	923	GGC	102;102;103	G;G,A;C	97;98,1;95	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1324	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3963	99.9	1	SNP	p	D95G	1	.	.	283	285	GGC	921	923	GGC	102;102;103	G;G,A;C	97;98,1;95	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	768	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1851	124.0	0	.	p	.	0	D79N	NONSYN	235	237	GAT	853	855	AAT	217;217;217	A,G;A;T	202,1;200;197	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	768	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1851	124.0	1	SNP	p	G45D	0	.	.	133	135	GGC	751	753	GGC	203;202;203	G;G;C	185;181;183	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	508	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1611	94.5	0	.	n	.	0	A197.	DEL	197	197	A	878	878	A	188	A	175	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1452	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3597	121.0	0	.	p	.	0	E91G	NONSYN	271	273	GAG	873	875	GGG	166;166;165	G;G,A;G	147;144,1;147	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1452	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3597	121.0	1	SNP	p	D86N	0	.	.	256	258	GAC	858	860	GAC	167;168;168	G;A,G;C	148;138,1;150	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1452	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3597	121.0	1	SNP	p	S87I	0	.	.	259	261	AGT	861	863	AGT	168;168;168	A;G;T	145;148;147	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1452	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3597	121.0	1	SNP	p	S87W	0	.	.	259	261	AGT	861	863	AGT	168;168;168	A;G;T	145;148;147	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1452	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3597	121.0	1	SNP	p	S87R	0	.	.	259	261	AGT	861	863	AGT	168;168;168	A;G;T	145;148;147	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1452	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3597	121.0	1	SNP	p	S88P	0	.	.	262	264	TCC	864	866	TCC	168;167;168	T;C;C	148;151;144	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1292	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3317	116.7	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1911	1913	CAC	145;146;146	C;A;C	131;130;131	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1292	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3317	116.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1860	1862	GGC	151;151;151	G,T;G;C	133,1;129;131	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	27	1176	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	122.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1461	1463	GCA	181;180;181	G,A,T;C,A;A	164,1,1;159,1;165	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1176	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	122.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1464	1466	ATC	180;180;180	A;T,G;C	164;157,1;163	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1176	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	122.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1476	1478	GTG	175;175;176	G;T,G;G	163;159,1;159	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1176	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	122.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1476	1478	GTG	175;175;176	G;T,G;G	163;159,1;159	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1176	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	122.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1980	1982	ACC	150;151;152	A,C;C,A;C	134,2;136,1;139	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1176	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	122.8	1	SNP	p	T502P	0	.	.	1504	1506	ACG	2034	2036	ACG	156;156;156	A;C;G,T	129;132;130,1	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1176	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	122.8	1	SNP	p	T502V	0	.	.	1504	1506	ACG	2034	2036	ACG	156;156;156	A;C;G,T	129;132;130,1	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1176	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	122.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2157	2159	GGC	158;158;158	G,C;G;C,G	133,1;140;141,1	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1176	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	122.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2166	2168	GGC	164;164;163	G,C,A;G;C	136,2,1;141;145	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	1176	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	122.8	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2184	2186	CTG	156;156;156	C,G;T;G	134,1;139;141	penA.44.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1624	ponA	2397	2397	100.0	ponA.l6.c17.ctg.1	3655	133.0	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1945	1947	CCG	162;163;160	C;C,A;G	134;141,1;142	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	740	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2519	88.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	972	972	C	130	C	121	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	122	porB1a	984	287	90.38	porB1a.l6.c4.ctg.1	1508	23.3	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1244	1246	AAT	17;17;17	A;A;T	15;15;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	122	porB1a	984	287	90.38	porB1a.l6.c4.ctg.1	1508	23.3	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1247	1249	AAT	17;17;17	A,G;A;T	13,1;13;15	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	122	porB1a	984	287	90.38	porB1a.l6.c4.ctg.1	1508	23.3	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1271	1273	GCA	17;17;17	G;C;A	15;14;15	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	122	porB1a	984	287	90.38	porB1a.l6.c4.ctg.1	1508	23.3	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1294	1296	GTA	16;16;16	G;T;A	15;15;15	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	122	porB1a	984	287	90.38	porB1a.l6.c4.ctg.1	1508	23.3	0	.	p	.	0	S236N	NONSYN	706	708	AGC	1300	1302	AAC	16;16;16	A;A;C	14;15;15	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	122	porB1a	984	287	90.38	porB1a.l6.c4.ctg.1	1508	23.3	0	.	p	.	0	.	MULTIPLE	709	711	AAC	1304	1308	TGGCG	15;15;15;15;15	T;G;G;C;G	14;14;14;14;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	122	porB1a	984	287	90.38	porB1a.l6.c4.ctg.1	1508	23.3	0	.	p	.	0	D238A	NONSYN	712	714	GAT	1310	1312	GCT	14;14;14	G;C;T	14;14;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	122	porB1a	984	287	90.38	porB1a.l6.c4.ctg.1	1508	23.3	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1370	1372	TTA	13;13;13	T;T;A	11;13;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	122	porB1a	984	287	90.38	porB1a.l6.c4.ctg.1	1508	23.3	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1415	1417	CAT	9;9;9	C;A;T	9;8;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	122	porB1a	984	287	90.38	porB1a.l6.c4.ctg.1	1508	23.3	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1418	1420	AGT	9;9;9	A;G;T	8;9;8	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	122	porB1a	984	287	90.38	porB1a.l6.c4.ctg.1	1508	23.3	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1427	1429	TAC	9;9;9	T;A;C	9;9;9	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	992	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2020	144.9	0	.	p	.	0	T26A	NONSYN	76	78	ACC	630	632	GCC	230;231;231	G;C;C	204;208;202	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	992	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2020	144.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	666	668	GAA	221;221;218	G;A;A	202;205;205	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	992	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2020	144.9	0	.	p	.	0	N124S	NONSYN	370	372	AAT	924	926	AGT	187;186;186	A;G;T	173;167;168	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	992	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2020	144.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	954	956	GAT	183;181;180	G;A,G;T	166;166,1;163	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	992	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2020	144.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1077	1079	TCA	169;171;172	T;C;A,C	153;153;157,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	992	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2020	144.9	0	.	p	.	0	D212Y	NONSYN	634	636	GAT	1188	1190	TAT	163;162;163	T,G;A;T	149,1;149;153	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	992	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2020	144.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1206	1208	GTC	160;160;160	G;T;C	152;151;154	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	992	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2020	144.9	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1218	1220	TCT	163;164;165	T;C,A;T	158;155,1;157	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	992	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2020	144.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1536	1538	GCA	171;172;172	G;C,T,G;A	161;155,1,1;154	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	992	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2020	144.9	1	SNP	p	G120K	1	.	.	358	360	AAG	912	914	AAG	191;191;190	A,T;A,C;G	173,1;176,1;172	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	992	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2020	144.9	1	SNP	p	D121N	0	.	.	361	363	GAC	915	917	GAC	191;191;191	G;A,C;C	172;172,1;168	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	992	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	2020	144.9	1	SNP	p	A121D	1	.	.	361	363	GAC	915	917	GAC	191;191;191	G;A,C;C	172;172,1;168	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2906	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5411	160.7	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2272	2274	CAT	156;154;155	C;A;T	135;136;136	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	494	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1574	94.2	1	SNP	p	V57M	1	.	.	169	171	ATG	794	796	ATG	189;190;191	A;T;G	173;179;174	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
